Kriya Secures $320M Series D to Advance Gene Therapies for Chronic Diseases
Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering gene therapies for chronic diseases, has announced the closing of a $320 million Series D financing. The oversubscribed round was co-led by Patient Square Capital and Premji Invest, with participation from high-profile investors including Peter Thiel, Narya Capital, and The T1D Fund.
The funding represents a significant step up from previous rounds and signals strong investor confidence in Kriya’s growing pipeline and proprietary manufacturing platform. As part of the financing, Akshay Rai of Premji Invest has joined Kriya’s Board of Directors.
Funding to Accelerate Clinical Programs Across Multiple Disease Areas
Proceeds from the raise will support Kriya’s ongoing and planned clinical trials, which span a broad range of chronic conditions with high unmet medical needs. These include:
- Geographic Atrophy
- Thyroid Eye Disease
- Type 1 Diabetes
- Metabolic Associated Steatohepatitis (MASH)
- Trigeminal Neuralgia
Kriya’s therapies leverage targeted, locally delivered gene therapies designed to provide durable, disease-modifying treatment. The company’s efforts are powered by a proprietary, fully integrated manufacturing and R&D platform aimed at solving key industry challenges in scalability, cost, and purity.
Strategic Support from Life Sciences and Tech Investors
“Our investment thesis to co-lead Kriya’s Series D financing centered on the company’s advanced manufacturing platform, built to support the development and commercialization of gene therapies for prevalent diseases in large markets,” said Akshay Rai, Healthcare and Biotech Investor at Premji Invest. “We believe that Kriya has solved key challenges that have historically held back the field.”
Jim Momtazee, Managing Partner at Patient Square Capital, added: “We have been proud to support Kriya since 2021 and continue to be impressed by the team’s vision. This financing is a major inflection point as the company moves deeper into clinical development.”
Kriya’s platform continues to position the company as a front-runner in expanding the reach of gene therapy beyond rare diseases to more widespread, chronic conditions—potentially transforming treatment paradigms for millions of patients worldwide.